Helix BioPharma Corp. announced earnings results for the second quarter ended January 31, 2021. For the second quarter, the company announced operating loss was CAD 1.904 million compared to CAD 2.242 million a year ago. Net loss was CAD 2.492 million compared to CAD 2.231 million a year ago. Basic loss per share was CAD 0.02 compared to CAD 0.02 a year ago. For the half year, operating loss was CAD 4.291 million compared to CAD 4.462 million a year ago. Net loss was CAD 2.714 million compared to CAD 4.407 million a year ago. Basic loss per share was CAD 0.02 compared to CAD 0.04 a year ago. Basic loss per share from continuing operations was CAD 0.03 compared to CAD 0.04 a year ago.